Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Note 9 - Other Expenses (Details Textual)

v3.10.0.1
Note 9 - Other Expenses (Details Textual) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jun. 13, 2018
May 07, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement Line Items [Line Items]            
Research and development expense, license fee [1],[2]     $ 5,000
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member]            
Statement Line Items [Line Items]            
Research and development expense, license fee   $ 2,000        
CrystalGenomics [member] | Exclusive license to cg806 in China [member]            
Statement Line Items [Line Items]            
Research and development expense, license fee $ 3,000          
[1] On June 13, 2018, the Company paid $3.0 million in cash to CrystalGenomics to gain an exclusive license to develop and commercialize CG-806 in China. Future milestone payments are described in note 10.
[2] On May 7, 2018, under the license agreement with CrystalGenomics the Company, the Company paid the option fee of $2.0 million in cash to CrystalGenomics in order to exercise early the option and gain an exclusive license to develop and commercialize CG-806 in all territories outside of Korea and China. Future milestone payments are described in note 10.